Drug search by name

Procainamide capsules and Myelosuppression

Result of checking the interaction of drug Procainamide capsules and disease Myelosuppression for safety when used together.

Check result:

Procainamide capsules <> Myelosuppression

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Bone marrow suppression inducing granulocytopenia, anemia, and thrombocytopenia has occurred during administration of procainamide. Most event occurred at recommended dosages and within twelve weeks of initiation of procainamide therapy. Agranulocytosis has resulted in death in 20% to 25% of reported cases. Therapy with procainamide should be administered cautiously in patients with or predisposed to myelosuppression or any type of cytopenia. Clinical monitoring of hematopoietic function including complete blood counts prior to initiation of therapy and at weekly intervals for the first 3 months of therapy and periodically after that is necessary.

References:

"Product Information. Procan SR (procainamide)." Parke-Davis, Morris Plains, NJ.
Berger B, Hauser D "Agranulocytosis due to new sustained-release procainamide." Am Heart J 105 (1983): 1035-6
Danielly J, Dejong R, Radkemitchell LC, Uprichard ACG "Procainamide-associated blood dyscrasias." Am J Cardiol 74 (1994): 1179-80
Fleet S "Agranulocytosis, procainamide, and phenytoin." Ann Intern Med 100 (1984): 616-7
Meisner DJ, Carlson RJ, Gottlieb AJ "Thrombocytopenia following sustained-release procainamide." Arch Intern Med 145 (1985): 700-2
Reidy T, Upshaw J "Procainamide-induced agranulocytosis." South Med J 77 (1984): 1582-4
Christensen D, Palma L, Phelps K "Agranulocytosis, thrombocytopenia, and procainamide." Ann Intern Med 100 (1984): 918
Gabrielson RM, Leininger NR "Procainamide and neutropenia." Ann Intern Med 100 (1984): 766-7
Ellrodt A, Murata G, Riedinger M, et al "Severe neutropenia associated with sustained-release procainamide." Ann Intern Med 100 (1984): 197-201
Landrum EM, Siegert EA, Hanlon JT, Currie MS "Prolonged thrombocytopenia associated with procainamide in an elderly patient." Ann Pharmacother 28 (1994): 1172-6
"Product Information. Pronestyl (procainamide)." Apothecon Inc, Plainsboro, NJ.
Eisner E, Shahidi N "Immune thrombocytopenia due to a drug metabolite." N Engl J Med 287 (1972): 376-81
Hoyt R "Severe neutropenia due to sustained-release procainamide." South Med J 80 (1987): 1196-7
Scifman R, Garewal H, Shillinton D "Reticulocytopenic, Coombs' positive anemia induced by procainamide." Am J Clin Pathol 80 (1983): 66-8